All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Curevac AG's mRNA-based prostate cancer vaccine CV9104, long its lead candidate, failed to meet the primary endpoint of improving overall survival during a phase IIb trial. Progression-free survival in treated patients was similar to those in the placebo arm.